Event 
Partner 
Milestone 
2020-09-07
ACT Genomics Completed the First Closing of latest Round of Equity Financing
ACT Genomics is pleased to announce the completion of the first closing of the latest round of equity financing from a group of strategic investors including Aflac Ventures LLC and Kyoto University Innovation Capital.
Place:
Asia
2020-07-28
Information Security Policy
Strengthen personnel knowledge and ability, avoid data leakage and ensure that services are available
Place:
Taiwan
2020-06-20
A Joint Clinical Research Collaboration among ACT Genomics, Kaohsiung Medical University (KMU), and National Health Research Institutes (NHRI) Seeks to Investigate the Genomic Landscape of Melanoma in Taiwan
ACT Genomics, Kaohsiung Medical University (KMU), and National Health Research Institutes (NHRI) launched a joint clinical research collaboration aimed to establish comprehensive genomic profiles of Melanoma within the Taiwanese population
Place:
Taiwan
2020-06-05
ACT Genomics Is At A Fresh Turning Point Under COVID-19 In 2020 US BIO Digital
ACT Genomics is chosen by Taipei City Government as representative to join US BIO Digital, the world’s largest biotechnology exhibition, with OBI Pharma, belxbiopharma, NatureWise Biotech & Medicals, Far East Bio-tec and AcroMass Technology.
Place:
Taipei
2020-06-04
ACT Genomics' Achievements In Precision Medicine Are Recognized By LDTS In Taiwan
LDTS registration proves that ACT Genomics provides reliable clinical genomic profiling results with clinical value, and this effort successfully allows many cancer patients to get better treatment opportunities through application for new therapies
Place:
Taipei
2020-05-28
ACTGenomics is the first one to receive approval for laboratory-developed NGS tests and services (LDTS) in Taiwan
ACTGenomics performs high-quality sequencing services and ACTOnco® +、ACTDrug® +、ACTFusion™ 、ACTMonitor®Lung and ACTBRCA® / ACTBRCA® HRD are recognized by LDTS
Place:
Taiwan
2020-04-07
ACT Genomics' TMB harmonization result is published in the Journal for Immunotherapy of Cancer
ACT Genomics is the only Asian genomic profiling company contributing to TMB harmonization in TMB project led by Friends of Cancer Research and our flagship panel, ACTOnco®+, shows the lowest variability in TMB comparison.
Place:
USA
2020-03-03
ACTCerebra identifies targeted drug options for brain metastases
ACTCerebra, ACT Genomics’ latest genomic profiling service, sequences 40 druggable genes to create a new opportunity for physicians to identify the most effective targeted therapies based on past medical history.
Place:
Taiwan
2020-03-02
ACT Genomics Partners With Oncoshot To Drive Clinical Trial At A Strategic Level
To find the missing piece in accurate clinical trial matching, ACT Genomics partners with Oncoshot, Singapore medical start-up, to offer comprehensive molecular information for Oncoshot’s clinical trial platform in SEA.
Place:
Singapore
2020-02-12
A Joint Clinical Research Collaboration among Tokyo Medical and Dental University (TMDU), ACT Genomics, and ACTmed Seeks to Investigate the Cancer Genomic Landscape of Japanese Population
Tokyo Medical and Dental University (TMDU), ACT Genomics, and ACTmed launched a joint clinical research collaboration aimed to establish comprehensive genomic profiles of highly prevalent cancers within the Japanese population.
TMDU Bioresource Research C
Place:
Japan
